Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells

Jong Won Kim, Heather Sahm, Jinsam You, Mu Wang

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background: Overexpression of superoxide dismutase 1 (SOD1) has been shown to be one of the factors involved in causing cisplatin resistance in ovarian cancer. Reduction of SOD1 expression is expected to restore, at least partially, cisplatin sensitivity in ovarian cancer chemotherapy. Here, we explored the potential of RNAi as a therapy for reversal of cisplatin resistance. Materials and Methods: SOD1-specific small-interfering RNA (siRNA) was synthesized and transfected into cisplatin-resistant cell line A2780/CP prior to treatment with 15 μM cisplatin. Cell survival was assessed by clonogenic assay. Results: An enhanced cisplatin sensitivity was observed in the A2780/CP cells treated with SOD1-specific siRNA, compared to non-siRNA-treated or scrambled-siRNA-treated control cells. Conclusion: Specifically targeting SOD1 could lead to sensitization of cisplatin-resistant ovarian cancer cells, and SOD1 may be used as a potential target for chemosensitizers.

Original languageEnglish (US)
Pages (from-to)2577-2581
Number of pages5
JournalAnticancer Research
Issue number7
StatePublished - Jul 1 2010


  • Cisplatin
  • Drug resistance
  • Mass spectrometry
  • Ovarian cancer
  • Selected-reaction-monitoring
  • siRNA
  • Superoxide dismutase 1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells'. Together they form a unique fingerprint.

Cite this